A decoy mutant ACE2 designed to reduce COVID-19

A decoy mutant ACE2 designed to reduce COVID-19

The need for new coronavirus disease 2019 (COVID-19) therapeutic strategies continues, especially as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerge. Zhang and colleagues elegantly engineered a mutant angiotensin-converting enzyme 2 (ACE2) that competitively binds SARS-C...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Trends in pharmacological sciences (Regular ed.) 2022-09, Vol.43 (9), p.703-705
Hauptverfasser: Maishan, Mazharul, Lim, Diana L., Zimmerman, Guy A., Matthay, Michael A.
Format: Artikel
Sprache:eng
Schlagworte:
Angiotensin-Converting Enzyme 2 - genetics
Angiotensin-Converting Enzyme 2 - metabolism
Animals
ARDS
COVID-19 - prevention & control
COVID-19 therapy
Humans
Mice
Protein Engineering
SARS-CoV-2
Spike Glycoprotein, Coronavirus - metabolism
Spotlight
viral pneumonia
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The need for new coronavirus disease 2019 (COVID-19) therapeutic strategies continues, especially as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerge. Zhang and colleagues elegantly engineered a mutant angiotensin-converting enzyme 2 (ACE2) that competitively binds SARS-CoV-2 spike protein, reduces viral uptake by human lung cells, and ameliorates SARS-CoV-2-induced lung injury in mice expressing human ACE2.
ISSN:0165-6147
1873-3735
DOI:10.1016/j.tips.2022.02.010